- Home
- QTRX vs DSGN Comparison
QTRX vs DSGN Comparison
Compare QTRX & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTRX
- DSGN
- Stock Information
- Founded
- QTRX 2007
- DSGN 2017
- Country
- QTRX United States
- DSGN United States
- Employees
- QTRX N/A
- DSGN N/A
- Industry
- QTRX Biotechnology: Laboratory Analytical Instruments
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- QTRX Industrials
- DSGN Health Care
- Exchange
- QTRX Nasdaq
- DSGN Nasdaq
- Market Cap
- QTRX 233.5M
- DSGN 208.9M
- IPO Year
- QTRX 2017
- DSGN 2021
- Fundamental
- Price
- QTRX $5.85
- DSGN $4.02
- Analyst Decision
- QTRX Buy
- DSGN Hold
- Analyst Count
- QTRX 4
- DSGN 1
- Target Price
- QTRX $13.50
- DSGN $4.00
- AVG Volume (30 Days)
- QTRX 691.9K
- DSGN 97.8K
- Earning Date
- QTRX 08-07-2025
- DSGN 08-04-2025
- Dividend Yield
- QTRX N/A
- DSGN N/A
- EPS Growth
- QTRX N/A
- DSGN N/A
- EPS
- QTRX N/A
- DSGN N/A
- Revenue
- QTRX $135,688,000.00
- DSGN N/A
- Revenue This Year
- QTRX N/A
- DSGN N/A
- Revenue Next Year
- QTRX $14.28
- DSGN N/A
- P/E Ratio
- QTRX N/A
- DSGN N/A
- Revenue Growth
- QTRX 7.71
- DSGN N/A
- 52 Week Low
- QTRX $4.05
- DSGN $2.60
- 52 Week High
- QTRX $16.01
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- QTRX 50.18
- DSGN 52.03
- Support Level
- QTRX $5.09
- DSGN $3.95
- Resistance Level
- QTRX $5.84
- DSGN $4.44
- Average True Range (ATR)
- QTRX 0.38
- DSGN 0.25
- MACD
- QTRX -0.05
- DSGN 0.02
- Stochastic Oscillator
- QTRX 48.41
- DSGN 54.35
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.